LONDON, June 02, 2022 (GLOBE NEWSWIRE) -- The Social Anxiety Disorder (SAD Social Phobia) Clinical Trial Analysis market research report offered by GlobalData Plc provides an overview and top line data relating to the clinical trials on social anxiety disorder (SAD social phobia), including an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, sponsor type, and prominent drugs for in-progress trials (based on the number of ongoing trials).
Social Anxiety Disorder Clinical Trials Market Segmentation by Region
- North America
- Asia-Pacific
- Europe
- Middle East and Africa
- South and Central America
Social Anxiety Disorder Clinical Trials Market Analysis, by Region
For more regional insights, download a free report sample
Social Anxiety Disorder Clinical Trials Market Segmentation by G7 Countries
- USA
- UK
- Germany
- Canada
- Japan
- France
- Italy
Social Anxiety Disorder Clinical Trials Market Analysis, by G7 Countries
For more G7 country insights, download a free report sample
Social Anxiety Disorder Clinical Trials Market Segmentation by E7 Countries
- China
- India
- Russia
- Turkey
- Brazil
- Mexico
- Indonesia
Social Anxiety Disorder Clinical Trials Market Analysis, by E7 Countries
For more E7 country insights, download a free report sample
Leading Social Anxiety Disorder Clinical Trial Sponsors
- GlaxoSmithKline Plc
- The Lundbeck Foundation
- Viatris Inc
- Johnson & Johnson
- Novartis AG
- Pfizer Inc
- AstraZeneca Plc
- Aurobindo Pharma Ltd
- Korea Pharma Co Ltd
- Syneos Health Inc
Social Anxiety Disorder Clinical Trials Market Analysis, by Sponsors
To know more about key sponsors, download a free report sample
Social Anxiety Disorder Clinical Trials Market Segmentation by Prominent Drugs
- PH-94B
- escitalopram oxalate
- sertraline
- fluoxetine
- 3,4-methylenedioxymethamphetamine
- fluoxetine hydrochloride
Social Anxiety Disorder Clinical Trials Market Analysis, by Prominent Drugs
To know more about prominent drugs, download a free report sample
Social Anxiety Disorder Clinical Trials Market Overview
| Top Regions | North America, Asia-Pacific, Europe, Middle East and Africa, South and Central America, and Others |
| G7 Countries | USA, UK, Germany, Canada, Japan, France, and Italy |
| E7 Countries | China, India, Russia, Turkey, Brazil, Mexico, and Indonesia |
| Key Sponsors | GlaxoSmithKline Plc, The Lundbeck Foundation, Viatris Inc, Johnson & Johnson, Novartis AG, Pfizer Inc, AstraZeneca Plc, Aurobindo Pharma Ltd, Korea Pharma Co Ltd, and Syneos Health Inc |
| Prominent Drugs | PH-94B, escitalopram oxalate, sertraline, fluoxetine, 3,4-methylenedioxymethamphetamine, and fluoxetine hydrochloride |
Social Anxiety Disorder Clinical Trials Market Report Scope
- The report provides a snapshot of the global clinical trials landscape
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with the reason for unaccomplishment
- The report provides enrollment trends for the past five years
- The report provides the latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regard to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of the global clinical trials market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country level
FAQs
Which are the key regions in the social anxiety disorder trials market?
The key regions in the social anxiety disorder clinical trials market SAD social phobia clinical trials market are North America, Asia-Pacific, Europe, Middle East and Africa, South and Central America.
Which are the leading sponsors in the social anxiety disorder clinical trials market?
The leading sponsors in the social anxiety disorder clinical trials market are GlaxoSmithKline Plc, The Lundbeck Foundation, Viatris Inc, Johnson & Johnson, Novartis AG, Pfizer Inc, AstraZeneca Plc, Aurobindo Pharma Ltd, Korea Pharma Co Ltd, and Syneos Health Inc.
What are the prominent drugs in the social anxiety disorder clinical trials market?
The prominent drugs in the social anxiety disorder clinical trials market are PH-94B, escitalopram oxalate, sertraline, fluoxetine, 3,4-methylenedioxymethamphetamine, and fluoxetine hydrochloride.
Related Reports
- Opium (Opioid) Addiction Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update – Click here
- Appetite (Eating) Disorders – Global Clinical Trials Review, 2022 – Click here
- Trigeminal Neuralgia (Tic Douloureux) – Global Clinical Trials Review, 2022 - Click here
- Interstitial Cystitis (Painful Bladder Syndrome Bladder Pain Syndrome) – Global Clinical Trials Review, 2022 – Click here
- Carpal Tunnel Syndrome – Global Clinical Trials Review, 2022 – Click here
About us
GlobalData is a leading provider of data, analytics, and insights on the world's largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision makers to predict and navigate the future. This is why GlobalData's mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on GlobalData for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.
Media Contacts
GlobalData
Mark Jephcott
Head of PR EMEA
mark.jephcott@globaldata.com
cc: pr@globaldata.com
+44 (0)207 936 6400
